Opendata, web and dolomites

AutoCapSyn SIGNED

Capsule based machines for the automated synthesis of organic molecules for drug discovery and medicinal chemistry

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AutoCapSyn project word cloud

Explore the words cloud of the AutoCapSyn project. It provides you a very rough idea of what is the project "AutoCapSyn" about.

environmentally    benchtop    commercially    chain    ing    timesaving    ultimately    customer    scaffolds    sales    amount    capsule    structure    toxic    commercial    unsafe    marketing    safety    synthesises    unfriendly    simplify    countries    successful    automated    tiny    appropriate    optimal    continues    unpredictable    feasible    minus    biological    deeper    discovery    benefits    machine    capsules    machines    button    lower    technically    robustness    introduces    molecules    enclosed    launch    market    first    environment    touch    critical    gaining    leader    components    exploration    data    completion    minimised    flow    frequency    delays    feasibility    exposure    productivity    route    time    safer    size    synple    pricing    compatibility    expensive    declining    trained    safe    drug    amounts    flexibility    supply    goals    efficient    channels    offers    aid    rely    synthesis    prepare    form    protocols    purification    innovative    reaction    specialists    dynamics    chemical    agents    candidate    consuming   

Project "AutoCapSyn" data sheet

The following table provides information about the project.

Coordinator
SYNPLE CHEM AG 

Organization address
address: VLADIMIR-PRELOG-WEG 3, HCI F314
city: ZURICH
postcode: 8093
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNPLE CHEM AG CH (ZURICH) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Drug discovery continues to rely on the synthesis of tiny amounts of candidate molecules using unpredictable protocols that require highly trained specialists. As such, it remains expensive, time-consuming, unsafe, and environmentally unfriendly. Declining productivity, high costs, and safety issues, have driven a large amount of chemical synthesis to lower cost countries, which introduces delays and uncertainty in the drug discovery process, where the flexibility to rapidly prepare new molecules in response to biological data is critical to success.

In order to address these problems, Synple has developed an innovative, benchtop, capsule-based machine that synthesises new molecules at the touch of a button. This fully automated technology offers significant timesaving and productivity benefits. With all necessary components for the safe execution of the reaction and purification of the resulting products enclosed within the capsule, the user’s exposure to toxic agents will be minimised. Use of the automated machines with the innovative capsules will aid chemical research organisations as they can greatly simplify the way in which key chemical scaffolds are produced while providing a safer and more efficient work environment.

The first goal of this feasibility study is to determine if the technology is technically feasible in its current form (robustness and compatibility with customer’s current work flow). The second goal – exploration of the commercially feasibility − will be achieved by gaining a deeper insight in the market size and dynamics, as well as determining frequency of use. Upon successful completion of these goals, we aim to then establish the steps required for commercial launch. Key parameters include: defining the supply chain and pricing structure and identifying the most appropriate sales, marketing and distribution channels. Ultimately, Synple aims to use this feasibility study to identify the optimal route to becoming the market leader.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTOCAPSYN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AUTOCAPSYN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More